They came to discover that the MicroVAX hit ~70% of the performance at a fraction of the cost.
That was an expensive dead end.
"Production problems pushed back its release, by which time these fears had come true and newer microprocessors like DEC's own NVAX offered a significant fraction of the 9000's performance for a tiny fraction of the price.
"Roughly four dozen systems were delivered before production was discontinued, a massive failure. "